caffeic acid has been researched along with Parkinson Disease in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, JH; Hu, XL; Lin, J; Lv, XY; Wang, BL; Wang, H; Xiong, F; Ye, WC; Zhang, XQ | 1 |
| Benfeito, S; Borges, F; Chavarria, D; Garrido, J; Lima, C; Oliveira, PJ; Remião, F; Serrão, P; Soares, P; Soares-da-Silva, P | 1 |
| Feng, L; Liu, J; Wang, Q; Wu, Q; Yang, Z; Zhang, L; Zhang, Y | 1 |
| Benfeito, S; Borges, F; Cagide, F; Cunha-Oliveira, T; Deus, CM; Oliveira, PJ; Pereira, SP; Raimundo, N; Simões, RF; Teixeira, J | 1 |
| Gunjima, K; Hashida, K; Hori, O; Konishi, T; Matsugo, S; Nakamura, Y; Takakura, K; Tomiyama, R; Yamada, T | 1 |
| Fazili, NA; Naeem, A | 1 |
| Linseman, DA; Taram, F; Winter, AN | 1 |
| Cacciatore, I; Cantalamessa, F; Cerasa, LS; Cornacchia, C; Di Stefano, A; Giorgioni, G; Iannitelli, A; Nasuti, C; Ricciutelli, M; Sozio, P | 1 |
| Corona, G; Spencer, JP; Vauzour, D | 1 |
9 other study(ies) available for caffeic acid and Parkinson Disease
| Article | Year |
|---|---|
Synthesis and biological evaluation of clovamide analogues with catechol functionality as potent Parkinson's disease agents in vitro and in vivo.
Topics: Apoptosis; Catechols; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Structure-Activity Relationship; Tyrosine | 2019 |
Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor.
Topics: Amides; Antioxidants; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Parkinson Disease | 2022 |
Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Autophagy; Behavior, Animal; Brain; Caffeic Acids; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Gait; Humans; Male; MAP Kinase Kinase 4; Mice, Transgenic; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2 | 2019 |
A mitochondria-targeted caffeic acid derivative reverts cellular and mitochondrial defects in human skin fibroblasts from male sporadic Parkinson's disease patients.
Topics: Caffeic Acids; Fibroblasts; Humans; Male; Mitochondria; Oxidative Stress; Parkinson Disease | 2021 |
3,4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway.
Topics: Buthionine Sulfoximine; Caffeic Acids; Cell Line, Tumor; Dose-Response Relationship, Drug; Glutathione; Humans; Neuroblastoma; Neuroprotective Agents; Neurotoxins; NF-E2-Related Factor 2; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein Transport; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species | 2014 |
Anti-fibrillation potency of caffeic acid against an antidepressant induced fibrillogenesis of human α-synuclein: Implications for Parkinson's disease.
Topics: alpha-Synuclein; Anilino Naphthalenesulfonates; Antidepressive Agents; Caffeic Acids; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Parkinson Disease; Protein Aggregates; Protein Structure, Secondary | 2015 |
Neuroprotection comparison of chlorogenic acid and its metabolites against mechanistically distinct cell death-inducing agents in cultured cerebellar granule neurons.
Topics: Animals; Antioxidants; Apoptosis; Caffeic Acids; Cell Death; Chlorogenic Acid; Coffee; Coumaric Acids; Cytoplasmic Granules; Glutamic Acid; Gray Matter; Hydrogen Peroxide; Neurons; Neuroprotection; Neuroprotective Agents; Nitroprusside; Parkinson Disease; Primary Cell Culture; Rats; Rats, Sprague-Dawley | 2016 |
New L-dopa codrugs as potential antiparkinson agents.
Topics: Administration, Oral; Animals; Antioxidants; Antiparkinson Agents; Caffeic Acids; Carnosine; Corpus Striatum; Dopamine; Glutathione Peroxidase; Levodopa; Parkinson Disease; Rats; Superoxide Dismutase | 2008 |
Caffeic acid, tyrosol and p-coumaric acid are potent inhibitors of 5-S-cysteinyl-dopamine induced neurotoxicity.
Topics: Animals; Caffeic Acids; Cells, Cultured; Coumaric Acids; Dopamine; Flavonoids; Mice; Neurons; Neuroprotective Agents; Parkinson Disease; Phenylethyl Alcohol; Propionates; Wine | 2010 |